Background on the CARTITUDE-4 Trial of Cilta-Cel in Multiple Myeloma
Binod Dhakal, MD, MS, provides background on the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of patients with lenalidomide-refractory multiple myeloma.
Zeidan Recaps the Phase 3 IMerge Trial of Imetelstat in Lower-Risk MDS
Amer Zeidan, MBBS, discusses the rationale of studying imetelstat in the phase 3 IMerge trial in patients with lower-risk myelodysplastic syndrome.
CheckMate-77T Update: Nivolumab-Based Regimen Improves EFS in NSCLC
In the phase 3 CheckMate-77T trial, a neoadjuvant and adjuvant treatment strategy including nivolumab and chemotherapy improved survival in resectable stage IIA to IIIB non–small cell lung cancer.
Keeping Up With New Approvals for Prostate Cancer Awareness Month
For prostate cancer awareness month, Bamidele A. Adesunloye, MD, MS, and Evan Pisick, MD, discussed recent changes and new developments that have been added to the treatment landscape.
Dato-Dxd Shows Survival Improvements in HR+/HER2- Breast Cancer
The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor-positive, HER2-negative breast cancer were treated with datopotamab deruxtecan.
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in Advanced mUC
Seagen Inc., and Astellas Pharma Inc., report that both primary end points of the phase 3 EV-302 clinical trial have been met.
Pembrolizumab/Lenvatinib Shows No Survival Advantage in Metastatic, Nonsquamous NSCLC
The phase 3 LEAP-006 study of pembrolizumab plus lenvatinib and chemotherapy has missed its dual primary end points.
FDA Fast Tracks MWTX-003 for Polycythemia Vera Treatment
The FDA has granted fast track designation to MWTX-003 for the treatment of patients with polycythemia vera.
NXC-201 Gains FDA Orphan Drug Designation for AL Amyloidosis
NXC-201, a next-generation chimeric antigen receptor T-cell therapy, has potential to expand as treatment for patients with amyloid light chain amyloidosis.
Dosing Begins in Phase 1/2a Trial of CD40HVac in HPV+ Oropharyngeal Cancer
Two doses of CD40HVac, a therapeutic vaccine targeting dendritic cells, are being evaluated as treatment for HPV-positive oropharyngeal cancer in a phase 1/2a trial.
Phase 2 SCOPE Trial of SCIB1 Achieves Positive ORR in Advanced Melanoma
Positive objective response results were demonstrated in the first stage of the phase 2 SCOPE trial. Now, 27 additional patients with advanced melanoma will be treated with SCIB1 and checkpoint inhibitors in stage 2.
Superior Outcomes Seen With Fixed-Duration Ibrutinib/Venetoclax in CLL
In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.
Exploration of PLK1 Inhibition in Advanced Cancers Begins
The investigational PLK1 inhibitor, CYC140, is the focus of important clinical research in advanced solid tumors, leukemias, and lymphomas.
Behind the FDA Approval: Momelotinib for Myelofibrosis and Anemia
In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, delves further into the background of momelotinib, how to manage toxicities with the agent, and its role in clinical practice moving forward.
Key Biomarkers Driving Treatment of Endometrial Cancer
In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the endometrial cancer landscape and future projections.
Biological Factors Affect CDK4/6 Inhibitor Response in Breast Cancer
Results from a new study could lead to the development of biomarkers for predicting treatment response and the implementation of strategies to address acquired resistance of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer.
Erdafitinib’s ‘Time to Shine’ in FGFR-Altered Urothelial Cancer
In an interview with Targeted Oncology, Arlene O. Siefker-Radtke, MD, discusses the findings from 3 trials of erdafitinib and explains the next steps for evaluating the agent.
FDA Grants Priority Review to Pembrolizumab/Chemoradiotherapy in Cervical Cancer
A supplemental biologics license application seeking the approval of pembrolizumab, external beam radiotherapy, and concurrent chemotherapy, followed by brachytherapy has been accepted for priority review by the FDA for advanced cervical cancer.
Novel SHP2/KRAS G12C Inhibitor Combo Yields Responses in KRAS G12C+ Solid Tumors
Based on safety and efficacy data from KontRASt-01 trial, the SP2/KRAS G12C inhibitor regimen will be investigated future.
Trastuzumab Deruxtecan Revolutionizes Treatment in HER2+ Breast Cancer
In an interview with Targeted Oncology, Sara A. Hurvitz, MD, discusses the impact of trastuzumab deruxtecan, new developments, and unmet needs in the HER2-positive breast cancer space.
FDA Okays Study of OSM-0205 to Prevent Chemo-Induced Peripheral Neuropathy
A phase 1 trial will evaluate OSM-0205 in healthy subjects with chemotherapy-induced peripheral neuropathy, followed by a phase 2 study in patients with breast cancer.
FDA to Conduct a Quick Review of sNDA for Belzutifan in Advanced RCC
A speedy review of an approval application for belzutifan has been undertaken by the FDA.
Nivolumab/Ipilimumab Continues to Show OS Benefit in NSCLC at 6 Years
With a minimum of 73.5 months of follow-up, nivolumab plus ipilimumab showed a benefit in overall survival in patients with treatment-naive stage IV or recurrent non–small cell lung cancer with no known EGFR/ALK alterations.
Gerds Provides Advice on Newly-Approved Momelotinib for Myelofibrosis
Aaron T. Gerds, MD, MS, provides advice to community oncologists on how to utilize momelotinib for patients with myelofibrosis.
Atezolizumab Combo Shows Potential in Advanced NSCLC With Brain Metastases
Atezolizumab, carboplatin, and pemetrexed demonstrated efficacy and safety in patients with advanced lung cancer with untreated brain metastases.
FDA Okays Plans to Address Clinical Hold of the HEMO-CAR-T IND
HEMO-CAR-T is an autologous chimeric antigen receptor T-cell therapy being developed against an acute myeloid leukemia target.
The Evolving Endometrial Cancer Treatment Paradigm
Adding immunotherapy to chemotherapy is the new standard-of-care treatment for advanced or recurrent endometrial cancer, according to Eirwen Miller, MD.
Mechanisms of Resistance to Noncovalent BTK Inhibitors in CLL
Skye Montoya, discusses research that she was a part of on mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Significant Benefit Shown with Perioperative Durvalumab/Chemo in Resectable NSCLC
According to research led by Tetsuya Mitsudomi, MD, perioperative durvalumab plus chemotherapy may be better than placebo plus chemotherapy for the treatment of resectable non–small cell lung cancer.
FDA Approves Momelotinib for the Treatment of Myelofibrosis and Anemia
Momelotinib has emerged as a new FDA-approved treatment option for patients with myelofibrosis and anemia.
2 Clarke Drive Cranbury, NJ 08512